See more : Kronologi Asia Berhad (0176.KL) Income Statement Analysis – Financial Results
Complete financial analysis of SpringWorks Therapeutics, Inc. (SWTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SpringWorks Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hokkaido Coca-Cola Bottling Co.,Ltd. (2573.T) Income Statement Analysis – Financial Results
- A&D HOLON Holdings Company Limited (7745.T) Income Statement Analysis – Financial Results
- AutoWeb, Inc. (AUTO) Income Statement Analysis – Financial Results
- Blonder Tongue Laboratories, Inc. (BDRL) Income Statement Analysis – Financial Results
- Eurotech, Ltd. (EUOT) Income Statement Analysis – Financial Results
SpringWorks Therapeutics, Inc. (SWTX)
About SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.45M | 6.15M | 0.00 | 35.00M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 422.00K | 1.90M | 490.00K | 349.00K | 192.00K | 17.33K | 3.18K |
| Gross Profit | 5.03M | 4.25M | -490.00K | 34.65M | -192.00K | -17.33K | -3.18K |
| Gross Profit Ratio | 92.25% | 69.16% | 0.00% | 99.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 150.49M | 146.12M | 101.68M | 51.86M | 42.55M | 9.90M | 2.80M |
| General & Administrative | 197.55M | 134.55M | 71.79M | 29.47M | 16.69M | 8.59M | 5.58M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.73M |
| SG&A | 197.55M | 134.55M | 71.79M | 29.47M | 16.69M | 8.59M | 1.86M |
| Other Expenses | 0.00 | -138.00K | -152.00K | 25.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 348.04M | 280.67M | 173.47M | 81.32M | 59.24M | 18.49M | 4.66M |
| Cost & Expenses | 348.46M | 280.67M | 173.47M | 81.32M | 59.24M | 18.49M | 4.66M |
| Interest Income | 22.95M | 6.15M | 698.00K | 1.33M | 3.55M | 678.00K | 63.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.67M | 1.90M | 490.00K | 349.00K | 192.00K | 17.33K | 3.18K |
| EBITDA | -341.35M | -280.67M | -172.98M | -45.98M | -59.05M | -18.47M | -4.64M |
| EBITDA Ratio | -6,266.68% | -4,566.03% | 0.00% | -131.36% | 0.00% | 0.00% | 0.00% |
| Operating Income | -343.01M | -280.67M | -173.47M | -46.32M | -59.24M | -18.49M | -4.66M |
| Operating Income Ratio | -6,297.28% | -4,566.03% | 0.00% | -132.35% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.91M | 3.26M | -442.00K | 750.00K | 933.00K | 678.00K | 21.00K |
| Income Before Tax | -325.10M | -277.42M | -173.91M | -45.57M | -58.31M | -17.81M | -4.64M |
| Income Before Tax Ratio | -5,968.50% | -4,513.05% | 0.00% | -130.21% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.26M | -698.00K | -1.33M | -3.55M | 678.00K | -2.00 |
| Net Income | -325.10M | -274.16M | -173.21M | -44.24M | -54.76M | -17.81M | -4.64M |
| Net Income Ratio | -5,968.50% | -4,460.06% | 0.00% | -126.41% | 0.00% | 0.00% | 0.00% |
| EPS | -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.80 | -0.11 |
| EPS Diluted | -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.80 | -0.11 |
| Weighted Avg Shares Out | 63.12M | 53.29M | 48.50M | 43.30M | 43.01M | 22.20M | 43.23M |
| Weighted Avg Shares Out (Dil) | 63.12M | 53.29M | 48.50M | 43.30M | 43.01M | 22.20M | 43.23M |
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect?
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports